# Long-Term Follow-Up Defines the Population That Benefits from Early Interception in a High-Risk Smoldering Multiple Myeloma Clinical Trial Using the Combination of Ixazomib, Lenalidomide, and Dexamethasone.

- Running/Short title: Ixazomib, Lenalidomide, Dexamethasone in HR-SMM
- 7
- 8 Authors: Omar Nadeem<sup>1\*</sup>, Michelle P. Aranha<sup>1,4\*</sup>, Robert Redd<sup>2</sup>, Michael Timonian<sup>1,4</sup>,
- 9 Sophie Magidson<sup>1</sup>, Elizabeth D. Lightbody<sup>1,4</sup>, Jean-Baptiste Alberge<sup>1,4</sup>, Luca Bertamini<sup>1</sup>,
- 10 Ankit K. Dutta<sup>1</sup>, Habib El-Khoury<sup>1</sup>, Mark Bustoros<sup>1,3</sup>, Jacob P. Laubach<sup>1</sup>, Giada Bianchi<sup>1</sup>,
- 11 Elizabeth O'Donnell<sup>1</sup>, Ting Wu<sup>4</sup>, Junko Tsuji<sup>4</sup>, Kenneth Anderson<sup>1</sup>, Gad Getz<sup>4</sup>, Lorenzo
- 12 Trippa<sup>2</sup>, Paul G. Richardson<sup>1</sup>, Romanos Sklavenitis-Pistofidis<sup>1,4</sup>, and Irene M. Ghobrial<sup>1</sup>
- 13
- <sup>14</sup> <sup>1</sup>Center for Early Detection and Interception of Blood Cancers, Department of Medical
- 15 Oncology, Dana-Farber Cancer Institute, Boston, MA, USA
- <sup>16</sup> <sup>2</sup>Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute,
- 17 Boston, MA, USA
- <sup>18</sup> <sup>3</sup>Division of Hematology and Medical Oncology, Meyer Cancer Center, New York-
- 19 Presbyterian Hospital, New York, New York, USA
- 20 <sup>4</sup> Broad Institute, Boston, MA, USA
- 21
- 22 \*Co-first author
- 23
- 24 Corresponding Authors:
- 25 Irene Ghobrial, MD
- 26 Dana-Farber Cancer Institute
- 27 450 Brookline Ave,
- 28 Boston, MA
- 29 irene\_ghobrial@dfci.harvard.edu\_
- 30 Phone: 617-632-4198
- 31

Omar Nadeem, MD Dana-Farber Cancer Institute 450 Brookline Ave, Boston, MA omar\_nadeem@dfci.harvard.edu Phone: 617-632-4952

#### 32 Abstract

Background: Early therapeutic intervention in high-risk SMM (HR-SMM) has 33 34 demonstrated benefit in previous studies of lenalidomide with or without dexamethasone. Triplets and quadruplet studies have been examined in this same population. However, 35 to date, none of these studies examined the impact of depth of response on long-term 36 outcomes of participants treated with lenalidomide-based therapy, and whether the use 37 38 of the 20/2/20 model or the addition of genomic alterations can further define the 39 population that would benefit the most from early therapeutic intervention. Here, we 40 present the results of the phase II study of the combination of ixazomib, lenalidomide, 41 and dexamethasone in patients with HR-SMM with long-term follow-up and baseline 42 single-cell tumor and immune sequencing that help refine the population to be treated for 43 early intervention studies.

44 Methods: This is a phase II trial of ixazomib, lenalidomide, and dexamethasone (IRD) in 45 HR-SMM. Patients received 9 cycles of induction therapy with ixazomib 4mg on days 1. 46 8, and 15; lenalidomide 25mg on days 1-21; and dexamethasone 40mg on days 1, 8, 15, 47 and 22. The induction phase was followed by maintenance with ixazomib 4mg on days 1, 48 8, and 15; and lenalidomide 15mg d1-21 for 15 cycles for 24 months of treatment. The 49 primary endpoint was progression-free survival after 2 years of therapy. Secondary 50 endpoints included depth of response, biochemical progression, and correlative studies 51 included single-cell RNA sequencing and/or whole-genome sequencing of the tumor and 52 single-cell sequencing of immune cells at baseline.

53 **Results:** Fifty-five patients, with a median age of 64, were enrolled in the study. The 54 overall response rate was 93%, with 31% of patients achieving a complete response and 55 45% achieving a very good partial response or better. The most common grade 3 or greater treatment-related hematologic toxicities were neutropenia (16 patients: 29%), 56 57 leukopenia (10 patients; 18%), lymphocytopenia (8 patients; 15%), and thrombocytopenia 58 7%). (4 patients: Non-hematologic grade 3 or greater toxicities included 59 hypophosphatemia (7 patients; 13%), rash (5 patients; 9%), and hypokalemia (4 patients; 60 7%). After a median follow-up of 50 months, the median progression-free survival (PFS) 61 was 48.6 months (95% CI: 39.9 - not reached; NR) and median overall survival has not 62 been reached. Patients achieving VGPR or better had a significantly better progression-63 free survival (p<0.001) compared to those who did not achieve VGPR (median PFS 58.2 64 months vs. 31.3 months). Biochemical progression preceded or was concurrent with the 65 development of SLiM-CRAB criteria in eight patients during follow-up, indicating that 66 biochemical progression is a meaningful endpoint that correlates with the development of end-organ damage. High-risk 20/2/20 participants had the worst PFS compared to low-67 and intermediate-risk participants. The use of whole genome or single-cell sequencing of 68 tumor cells identified high-risk aberrations that were not identified by FISH alone and 69 70 aided in the identification of participants at risk of progression. scRNA-seq analysis revealed a positive correlation between MHC class I expression and response to 71 72 proteasome inhibition and at the same time a decreased proportion of GZMB+ T cells 73 within the clonally expanded CD8+ T cell population correlated with suboptimal response.

**Conclusions**: Ixazomib, lenalidomide and dexamethasone in HR-SMM demonstrates significant clinical activity with an overall favorable safety profile. Achievement of VGPR or greater led to significant improvement in time to progression, suggesting that achieving deep response is beneficial in HR-SMM. Biochemical progression correlates with endorgan damage. Patients with high-risk FISH and lack of deep response had poor outcomes. ClinicalTrials.gov identifier: (NCT02916771)

80

Funding: Takeda and Celgene (Bristol Myers Squibb) provided support for the clinical trial. These funders reviewed the final manuscript and approved its publication; they were not involved in the conceptualization, design, data collection, analysis, or preparation of the manuscript. Funding was also provided by the Dr. Miriam and Sheldon G. Adelson

85 Medical Research Foundation and the NIH (R35CA263817 awarded to I.M.G.).

86

#### 87 Introduction

#### 88

89 Smoldering multiple myeloma (SMM), defined by the presence of  $\geq$  10% clonal plasma 90 cells in the bone marrow and/or  $\geq$  3g/dl monoclonal (M) protein in the serum without the 91 presence of any myeloma-defining events (MDE), carries a heterogenous risk of 92 progression to overt multiple myeloma (MM), with an average risk of 10% per year for the 93 first 5 years after diagnosis and then approximately 1-2% per year thereafter<sup>1</sup>. There is a 94 subset of patients that are considered high-risk SMM (HR-SMM) and multiple efforts have 95 been undertaken to further define this high-risk group, which carries an approximately 96 50% risk of progression to overt MM at 2 years. The Mayo 2008 criteria defined HR-SMM 97 as having  $\geq 10\%$  plasmacytosis, M protein  $\geq 3$  g/dl, and an SFLC ratio  $\geq 8$  or  $\leq 0.125^2$ . 98 Many additional risk models have been studied including the PETHEMA criteria, evolving 99 criteria, and IgA subtype, all of which were also shown to have prognostic relevance<sup>3</sup>. A 100 study by Rajkumar et al. compiled all the high-risk features of SMM to help define this population<sup>4</sup>. Later, the IMWG/Mayo 2018 criteria were revised and defined high risk as 101 102 having the presence of at least 2 of the following 3 criteria: bone marrow plasmacytosis >20%, M protein >2 g/dl, and an SFLC ratio >20<sup>5,6</sup>. While these models help identify 103 104 patients at high risk of progression, they mostly leverage clinical variables and can give 105 discordant results for an individual<sup>7</sup>. Prediction models that take into account disease 106 biology may be able to overcome some of these challenges. In recent years for example, 107 MYC translocations and copy number abnormalities, KRAS mutations, Del17p and TP53 108 mutations, as well as APOBEC activity and chromothripsis have been shown to portend 109 a higher risk of progression<sup>8-12</sup>.

110

111 Management of SMM has historically consisted of observation. However, with advances 112 in risk stratification methods and MM therapy, early therapeutic intervention may offer an 113 improved prognosis without morbidity from MM for high-risk patients. There have been 2 114 phase III trials utilizing lenalidomide or lenalidomide and dexamethasone in patients with 115 HR-SMM. Both studies demonstrated improvement in progression-free survival (PFS), 116 and one also demonstrated improvement in overall survival, further arguing for early intervention<sup>13,14</sup>. While the prolongation of overall survival with early intervention is a 117 118 subject of debate, prolonging progression-free survival may delay end-organ damage 119 which can be irreversible and can severely impact a patient's quality of life<sup>15-17</sup>.

120

121 Following these two randomized studies, multiple phase II studies using triplet or more recently guadruplet therapy have been initiated in high-risk SMM<sup>18-21</sup>. However, there are 122 123 many unresolved questions about the optimal management of patients with HR-SMM, 124 particularly regarding the use of response assessment metrics that were originally 125 developed in patients with overt MM, such as depth of response and biochemical 126 progression, as well as determining the group of patients who may benefit the most from 127 early intervention. The studies using lenalidomide with or without dexamethasone had 128 low rates of complete response and therefore could not assess the role of depth of 129 response in long-term follow-up. Additionally, more recent studies using quadruplet 130 therapy do not have enough long-term follow-up to assess this question yet. Here, we 131 used the combination of ixazomib, lenalidomide, and dexamethasone in high-risk SMM. 132 We aimed to help address several critical questions for therapeutic intervention in HR-

133 SMM: 1) whether depth of response (VGPR or CR) matters in the long-term outcome of patients treated with a lenalidomide-based therapy, 2) whether biochemical progression 134 135 correlates with end-organ damage, 3) whether 20/2/20 defines participants who would 136 benefit the most from early intervention with lenalidomide-based therapy, and 4) whether 137 the addition of genomic biomarkers can improve the risk stratification of these participants 138 enrolled on these studies.

- 139
- 140

#### 141 Results

- 142
- 143 Baseline characteristics.
- 144

145 Between March 2017 and February 2020, 55 patients were enrolled on this study (Figure 146 **1A**). Patient baseline characteristics, definition of high-risk SMM, and high-risk 147 cytogenetics are summarized in **Table 1A**. The median age was 64 (range 40-84) with 148 30 (55%) males and 25 (45%) females. All patients had an Eastern Cooperative Oncology 149 Group (ECOG) performance status of  $\leq 1$ . Patients were enrolled using the list of high-risk 150 criteria compiled by Raikumar et al<sup>4</sup>. For cross-study comparisons, we defined patients with high-risk disease based on several validated models in **Table 1B**, including the Mayo 151 152 2008, Mayo 2018, IMWG risk score tool, and high-risk cytogenetics. High risk FISH was 153 defined as follows: gain1q, del13q, del17p, del1p, t(4;14), t(14;16).

154

155 While FISH testing is a standard method to define risk in MM, the failure rate of FISH in 156 this study was 36% (FISH at screening was successful in 35/55) (Figure 1B). Therefore, 157 we employed whole genome sequencing (WGS) and single-cell RNA (scRNA) sequencing to identify high-risk translocations and copy number alterations (CNA). The 158 159 translocations and copy number alterations identified by FISH, WGS, and scRNA-seg are displayed in **Figure 1B.** From scRNA-seq, we leveraged the expression level of primary 160 IgH translocation marker genes to infer the presence of translocations and observed high 161 162 concordance between the expression of said marker genes and FISH results, but 163 additionally detected translocations in three patients in whom FISH had failed due to low cell numbers. Furthermore, using Numbat<sup>22</sup> to infer CNAs from scRNA-seg data, we 164 165 detected hyperdiploidy (homologous recombination deficiency: HRD) in another four patients in whom FISH had failed due to low cell numbers, as well as additional high-risk 166 167 secondary CNVs such as Amp1q, Del13q, and Del1p in four patients. Whole-genome 168 sequencing confirmed the IgH translocations, hyperdiploidy, and secondary CNVs in 10 169 patients with both WGS and scRNA-seq of tumor cells. No discrepancies were observed 170 between scRNA-seg and WGS. Overall, for ten patients where FISH failed due to a low 171 number of cells, scRNA-seq and WGS data existed and we were able to resolve the 172 cytogenetic abnormalities for these cases. Notably, the first aspirate pull was used for 173 clinical-grade FISH testing, while later pulls were used for research-level WGS and 174 scRNA-seq; given the frequent hemodilution observed in later aspirate pulls which further 175 decreases the number of tumor cells in the specimen, these results showcase the 176 superior sensitivity in tumor cell detection and characterization of these methods 177 compared to FISH. Further, by reviewing pre-screening FISH reports and incorporating 178 primary translocation data from treatment records for remaining failures, we obtained

cytogenetic data for 49 out of 55 individuals. Since we did not have whole-exome
sequencing or WGS data on all patients, we refrained from assessing the impact on
outcomes of certain high-risk mutations, including MAPK mutations, DNA repair
mutations, or MYC alterations, which have been previously identified as high risk<sup>8,10,12</sup>.

183 Safety

184 Toxicity results are summarized in Table 2. Thirty-six percent of patients experienced a 185 grade 2 toxicity, 62% experienced a grade 3 toxicity and 9% experienced a grade 4 toxicity. The most common treatment-related toxicities of any grade included leukopenia 186 187 in 44 patients (80%), neutropenia in 43 patients (78%), fatigue in 42 patients (76%), rash 188 in 38 patients (69%), and diarrhea in 37 patients (67%). The most common grade 3 189 treatment-related hematologic toxicities were neutropenia in 14 patients (25%), 190 leukopenia in 10 patients (18%), lymphopenia in 6 patients (11%), and thrombocytopenia 191 in 4 patients (7%). Non-hematologic grade 3 toxicities included hypophosphatemia in 7 192 patients (13%) and rash in 5 patients (9%). Grade 4 toxicities related to study treatment 193 included hyperglycemia (n = 1/55; 2%), hypokalemia (n = 1/55; 2%), lymphopenia (n = 194 2/55; 4%), neutropenia (n = 2/55; 4%), and thrombocytopenia (n = 1/55; 2%). One patient 195 developed a grade 5 intracranial hemorrhage 3 weeks after completion of therapy that was not related to the study intervention; the patient was on therapeutic anticoagulation 196 197 with a history of atrial fibrillation and the event was considered unrelated by the patient's 198 treating physicians.

199 Five patients developed secondary malignancies (one instance each of prostate, 200 head/neck, ovarian, uterine and melanoma). Three of five patients were diagnosed 201 following the completion of treatment on protocol and remained on follow-up while 202 receiving active treatment for secondary malignancy. The remaining two patients were 203 diagnosed during active treatment; one participant delayed treatment for secondary 204 malignancy (prostate) to finish protocol therapy and remained on study through the end 205 of protocol-based follow-up. The other patient diagnosed during active treatment 206 discontinued therapy to receive treatment for their secondary malignancy (melanoma) 207 and remained on follow-up. No patients were diagnosed with myelodysplastic syndrome 208 or other myeloid malignancies.

Dose modifications occurred in 34 patients (62%) during the study therapy. The median number of modifications was 1 (range 1-4) and dose delays due to toxicity occurred in 19 patients (35%). The most common reason for dose modification of ixazomib was peripheral neuropathy (10 patients, 18%). Stem cells were collected from all eligible patients by the end of the induction phase and there was one patient who failed to mobilize stem cells.

The median number of cycles completed was 24 (range: 2-24). Five patients discontinued therapy prior to the planned 24 cycles. Reasons for discontinuation included worsening unrelated co-morbid conditions (n=3), treatment for a different malignancy (n=1), and withdrawal of consent (n=1). No patients discontinued treatment due to toxicity.

#### 219 Efficacy

The overall response rate (partial response or better) based on International Myeloma 220 Working Group (IMWG) criteria<sup>23</sup> was 93% (n=51), with complete response (CR) 221 222 observed in 17 patients (31%), VGPR in 8 patients (15%), and partial response in 26 223 patients (47%) (Table 3). All patients who achieved CR also achieved a stringent and 224 sustained CR for at least 6 months with responses deepening over time (Figure 2). 225 Twenty-five patients (45%) achieved a VGPR or better response and minimal response 226 or better was observed in 98% of patients (n=54). The overall response rate was similar 227 for patients in different 20/2/20 risk groups: low (100%), intermediate (90%), and high 228 (92%) (Cochran-Armitage test, p=0.55).

229 Eight participants progressed to overt MM defined by the SLiM-CRAB myeloma-defining 230 events (MDEs)<sup>24</sup> (Figure 2). All eight patients experienced biochemical progression 231 concurrent with or prior to developing SLiM-CRAB progression (Figure 2). One patient 232 discontinued protocol therapy after one cycle due to unrelated comorbid conditions 233 including colitis and atrial fibrillation and remained on follow-up for ten months prior to 234 SLIM-CRAB progression. The remaining seven progressors completed all twenty-four 235 cycles of protocol therapy and continued on follow-up prior to progression. Four of eight 236 progressors had an MDE within one year of their final treatment, and the median time to 237 progression for the remaining four progressors was 21 months (range: 13.2-32.7 months). 238 Four patients developed lytic bone disease noted on PET and MRI during follow-up, one 239 patient developed renal failure and hypercalcemia 9 months after completion of therapy 240 (after showing biochemical progression at 6 months post-therapy), one patient developed 241 anemia 17 months post-therapy after showing biochemical progression at 6 months post-242 therapy, one patient met SLiM-CRAB criteria at 13 months post-therapy with FLC ratio > 243 100 and BMPCs of 60% prompting initiation of therapy and one patient met SLiM-CRAB 244 criteria at 13 months post-therapy with FLC ratio >100. Seven of the eight had at least 245 one high-risk genetic event at baseline [1q gain (n=4), Del13q (n=5), Del17p (n=2, one 246 confirmed from FISH tests and one identified in a pre-screening FISH report from patient 247 records), Del1p (n=3), t(14;16) (n=1), KRAS (n=2), TP53 (n=1)] (Figure 1B). Among all 248 progressors, the best response achieved was PR with none achieving VGPR or better.

249

#### 250 <u>Time-to-event analyses</u>

The median follow-up for all 55 patients was 50 months (range: 8-61 months). Thirty patients had biochemical progression events (**Figure 2**). Biochemical progression was defined as a 25% increase in serum or urine M protein or a difference between involved and uninvolved FLC levels based on the IMWG criteria<sup>25</sup>.

The total number of patients who were followed for at least two years and remained biochemical progression-free (including the censored patients who came off therapy with or without progression) was 50 of 55 patients (91%; 90% CI: 82 - 96%, p < 0.001, one-sided exact binomial test) (**Figure 3A**).

#### 259

260 Progression-free survival for the primary endpoint was defined as the development of 261 end-organ damage per the SLiM-CRAB criteria or death. Participants who were not followed for at least two years, yet remained alive and progression-free while on trial, 262 were censored at the last date known progression-free. The total number of patients who 263 264 remained progression-free without SLiM-CRAB criteria or death within two years of 265 enrollment was 52 of 53 patients (98%) (Figure 3B). One patient developed SLiM-CRAB 266 progression within 2 years of enrollment after discontinuing therapy (described above). 267 No patients developed SLiM-CRAB progression while on active therapy (Figure 3B).

Median biochemical PFS was 48.6 months (95% CI: 39.9 – not reached; NR) and median overall survival has not been reached **(Figure 3 A, C).** The median duration of response was 47.4 months (95% CI: 37 – NR) and the median time to progression was 49.9 months (95% CI: 39.9 – NR).

#### 272 Subsequent treatments for those with biochemical progression but not SLiM-CRAB

273 Eleven patients started new treatments on SMM-directed clinical trials following the 274 completion of protocol therapy prior to the development of SLIM-CRAB progression. Of 275 these, ten experienced biochemical progression while on follow-up (Figure 2) and had 276 an evolving pattern leading to enrollment in a subsequent clinical trial. Evolving pattern 277 was defined as an increase of 10% in the M-spike concentration or the involved free light 278 chain concentration during the 6 months prior to screening for the clinical trial. Four 279 patients met high-risk criteria per the 20/2/20 model on follow-up. These patients elected not to wait for end-organ damage on follow-up and proceeded with therapy on another 280 281 trial of HR-SMM.

#### 282 Factors that impact progression-free survival

283 We next assessed several baseline characteristics to determine factors that define the 284 population that benefits the most from a lenalidomide-based regimen and further 285 identified endpoints that can be early biomarkers for end-organ damage in this population. 286 We examined baseline characteristics including the 20/2/20 model, evolving subtype, 287 high-risk cytogenetics, the best response to therapy, as well as the combination of 288 response, high-risk cytogenetics, and minimal residual disease (MRD). These criteria 289 were used based on their association with prognosis in prior studies of overt MM in a prior 290 post hoc assessment in lenalidomide studies of SMM<sup>26,27</sup>.

We first determined whether the baseline 20/2/20 criteria helped identify patients who would have a prolonged PFS in response to therapy. We combined low- and intermediate--risk patients and compared them to high-risk patients. Here, we showed that the median PFS was longer but not statistically significant at 57.8 months for the low-/intermediaterisk group compared to 37.2 months for high-risk patients (log-rank, p = 0.08) (**Figure 3D**). The median duration of response was significantly shorter at 31.6 months in highrisk patients compared to 56.9 in the low/int group (log-rank, p = 0.046) (**Figure 3E**). 298 Evolving disease was assessed in all participants as part of the eligibility criteria and as 299 described above this was defined as a 10% or greater increase in either the M-spike 300 concentration or the involved free light chain concentration within the 6 months preceding 301 clinical trial screening. Of all patients that enrolled in the clinical trial (N=55), an evolving 302 pattern was found in 29 out of 55 patients (53%) while 26 out of the 55 patients (47%) did 303 not have an evolving pattern (**Table 1**). The median time of the lab result was 107 days 304 prior to the screening date with an interquartile range of 120 days. The presence of 305 evolving disease at baseline was similar across baseline IMWG 20/2/20 risk groups: low 306 (56%), intermediate (48%), and high (56%) (Cochran-Armitage, p=0.83). Of the patients 307 that demonstrated an evolving pattern, only 31% (n=9/29) achieved a VGPR or better, 308 and of those that did not demonstrate an evolving pattern, 62% (n=16/26) achieved a 309 VGPR or better (Fisher's exact, p=0.032).

In patients who did not demonstrate an evolving pattern, the PFS was significantly longer at 53.4 months compared to 40.1 months in those who had evolving disease prior to registration (log-rank, p=0.025). Additionally, in patients who did not demonstrate an evolving pattern, the median duration of response was not reached and was significantly longer compared to that in patients who had an evolving subtype (37.9 months; log-rank, p=0.034) (Figure 4A-D).

We next examined whether patients with VGPR or CR had an improved progression-free 316 317 survival. Response has been associated with PFS in studies of overt MM<sup>28</sup>. However, this 318 has not been previously shown in studies of smoldering myeloma partially because the 319 previous studies using lenalidomide and dexamethasone had few cases of CR and 320 partially for the short follow-up period of the guadruplet regimens being currently assessed in SMM. We, therefore, aimed to determine whether depth of response is 321 322 associated with progression in the SMM setting. Indeed, we demonstrated that patients 323 who showed VGPR or better had a median time to progression (TTP) of 58.2 months 324 compared to 31.3 months in patients who showed inferior responses (log rank, p < 0.001; 325 Figure 5 A). Interestingly, this was still true in patients with high-risk cytogenetics as 326 determined by FISH only (median PFS 31.3 months vs 53.4 months, log-rank, p = 0.002) 327 or by FISH and whole genome sequencing(WGS) (median PFS of 30.8 months vs 53.4 328 months, p < 0.001), demonstrating that depth of response is relevant for prognostication 329 independent of cytogenetics (Figure 5 B,C).

All patients who achieved a complete response (CR) maintained it for at least 6 months. The median duration of response in the sustained CR group was not reached at the time of analysis, while the median duration of response in the non-CR group was 35.5 months (log-rank, p = 0.0016) (**Figure 5D**). Similarly, the median progression-free survival in the sustained CR group was not reached, compared to 38 months in the non-CR group (logrank, p = 0.0018) (**Figure 5E**).

336

337 Minimal Residual Disease

338 Twenty-five patients were evaluable for MRD (achieved VGPR or better) by next-339 generation sequencing (NGS), 11 out of 25 had no samples available for MRD testing or 340 had a quality control (QC) failure. Twenty-three samples at C9 or EOT from 14 out of 25 341 patients passed the QC analysis and were available for MRD testing. A sensitivity of 10<sup>-5</sup> was reached in 22/23 (96%) samples and a sensitivity of 10<sup>-6</sup> in 17/23 samples (74%) 342 343 (Suppl Figure S1). Out of patients who showed a VGPR or better response and had 344 MRD testing (n=14), 29% (4/14) were MRD negative at  $10^{-5}$  at EOT and none developed 345 biochemical or clinical progression over the follow-up period. Of those who were MRD 346 positive at 10<sup>-5</sup> (n=10/14), 6 patients developed biochemical progression during the follow-347 up period. Two MRD time points (C9 and EOT) were available in a subgroup of 8 individuals. Of those, 50% (4/8) were MRD positive at 10<sup>-5</sup> at C9 and remained so at EOT, 348 349 while 50% (4/8) were MRD negative at 10<sup>-5</sup> at C9 but only 1 patient remained MRD 350 negative at EOT, and 3 converted to MRD positive. The 3 patients that converted from a 351 C9 MRD negative at a sensitivity of 10<sup>-5</sup> to positive at EOT developed biochemical progression during the follow-up period. The 5-year progression-free survival rate of 352 353 patients who achieved MRD negativity at 10<sup>-5</sup> was 100%, compared to 40% of MRD-354 positive patients (log-rank, p = 0.051) (**Figure 6**).

#### 355 Mass Spectrometry MRD assessment

MALDI-TOF mass spectrometry was available at baseline and C9 in 43 patients. The M-356 357 protein was undetectable in 4 patients at C9 (10%). Since clearance of M-protein could 358 take more time than tumor cell clearance in the BM, we tested the serum of patients by 359 MALDI-TOF in available serum samples during maintenance at 2-6 months after C9 (at 360 C11 to 16). 37 were retested during maintenance: six were negative (including the 4 that 361 were negative at C9) and 31 remained positive. At EOT, MALDI-TOF was performed for 41 patients. Eight (20%) were negative: 6 out of 8 confirmed a previous negative result, 362 363 one case turned negative from a previous positive result, and one had a negative result from baseline with no testing during treatment. The concentration calculated using the 364 365 EXENTi software positively correlated with that calculated via SPEP at diagnosis. C9 and EOT (p<0.0001) (Suppl Figure S3). Of the patients with negative MALDI-TOF at EOT 366 367 (n=8), 4 developed biochemical progression, and none developed SLiM-CRAB 368 progression. In patients who achieved a negative MALDI-TOF result at EOT, the median 369 progression-free survival was 53.46 months compared to 38.01 months in patients who 370 had a positive MALDI-TOF result at EOT (log-rank, p=0.08) (Suppl Figure S4).

371

We compared residual disease detection using serum immunofixation (IFX) with MALDI-TOF in 86 measurements. While both tests are significantly concordant (Table S1, Cohen's  $\kappa$ =0.64, p<0.001, 95% CI [0.44, 0.84]) and no patients had a positive IFX test and a negative MALDI-TOF test, MALDI-TOF identified some cases missed by IFX (10 IFX-negative MALDI-TOF-positive cases). Therefore, MALDI-TOF might be more sensitive than IFX for detecting residual disease.

378

## 379 Single-cell RNA sequencing reveals tumor-intrinsic and extrinsic factors 380 associated with disease progression

381

To identify biological predictors of response and resistance to IxaRD in baseline samples from patients with HR-SMM, we performed single-cell RNA sequencing on CD138+ and CD138- cells as well as WGS on 22 patients enrolled on the study (14 biochemical progressors, 8 non-progressors) and 11 Healthy donors (Figure 7A). Among the progressors in this subcohort, 5 patients met SLiM CRAB criteria (Figure 7A).

387

388 Overall, we identified 125,572 plasma cells(Patients: malignant, n=50,591; normal, 389 n=1876; HD: n=73,105) (Figure 7B-D). To identify tumor-intrinsic transcriptomic 390 alterations associated with biochemical progression post-IxaRD in patients with HRSMM. 391 we performed differential expression analysis comparing tumor cells from patients who 392 progressed (n=10) to those who did not (n=3). To restrict the influence of individual tumors 393 on the analysis, as well as to control for the lower number of non-progressors in this sub-394 cohort, we randomly sampled the same number of tumor cells from progressors and non-395 progressors (~2100 per group) and balanced the contribution of each individual towards 396 the group (progressors: ~210 cells per patient; non-progressors: 700 cells per patient; 397 Figure 7E). Additionally, to control for differences in sequencing depth, we downsampled 398 20K reads per cell across all cells used in this analysis. We observed consistently higher 399 expression levels of MHC class I genes (HLA-A, HLA-B, HLA-F, HLA-E, B2M) in tumor 400 cells from non-progressors to progressors (Figure 7E). To validate this observation, we 401 analyzed bulk RNA-sequencing data from an external cohort of MM patients treated with 402 a Bortezomib-based regimen, a different proteasome inhibitor (PADIMAC, GSE116234). 403 This analysis confirmed that tumor cells from patients who respond well to proteasome 404 inhibition show higher levels of MHC-I genes (Figure 7F). Notably, the PADIMAC study 405 did not use Lenalidomide in combination with proteasome inhibition, which was the case 406 in our study. This supports the notion that the observed association with MHC-I levels is 407 related to proteasome inhibition specifically rather than a particular combination.

408 These results suggest that antigen presentation via MHC-I by tumor cells may be 409 important for response to proteasome inhibition and implicate the immune system in 410 mediating response. While the immune system has been thought to potentiate the effects 411 of proteasome inhibition through increased neoantigen presentation by immune cells following tumor cell killing, it has not been previously linked to tumor-intrinsic 412 413 transcriptomic alterations<sup>29</sup>. To pursue this hypothesis further, we turned our attention to 414 the cytotoxic CD8+ T cell compartment, which is tasked with responding to MHC-I-bound 415 tumor-derived antigens. Overall, we sequenced 51,326 T-cells, including 5,045 granzyme 416 K (GZMK)-expressing and 9,026 granzyme B (GZMB)-expressing cytotoxic T cells 417 (Figure 7G). First, we systematically compared the frequency of clonal expansion within 418 the GZMK+ and the GZMB+ compartment between progressors and non-progressors. 419 We observed that the GZMK+ compartment was significantly more clonally expanded in 420 progressors compared to non-progressors (bootstrapping, two-sided p<0.001) (Figure **7H**), but this was not seen in the GZMB+ compartment. By comparing the frequency of 421 422 the GZMB+ phenotype within clonally expanded T cells from progressors and non-423 progressors, we observed a significant decrease in differentiation towards the GZMB+ 424 phenotype in progressors (Wilcoxon, two-sided p=0.048) (Figure 7 I, J). This suggests

that clonally expanded effector cytotoxic T cells from progressors may be less mature 425 compared to non-progressors. To gain more insight into the functionality of clonally 426 427 expanded GZMB+ cytotoxic T cells, we performed differential expression analysis 428 between progressors and non-progressors. We observed that clonally expanded GZMB+ 429 cytotoxic T cells from non-progressors showed higher expression levels of genes related 430 to cytotoxicity and activation, such as TYROBP, CXCR4, and members of the AP-1 431 pathway, compared to progressors (Figure 7K). Clonally expanded GZMB+ cytotoxic T 432 cells from progressors showed higher levels of GIMAP genes, which may be associated with increased apoptosis<sup>30</sup>, and *THEMIS*, which can suppress cytotoxic responses<sup>31</sup>, 433 434 however higher levels of maturation markers ITGB1 and CX3CR1 were also observed, 435 suggesting that the functionality of clonally expanded GZMB+ cytotoxic T cells may be 436 more nuanced.

Overall, this suggests that clonally expanded cytotoxic T cells from progressors are
phenotypically less mature, and potentially less functional, compared to those from nonprogressors, which could be related to the observed differences in MHC-I expression in
tumor cells. This data implicates immune dysfunction as a potential correlate of
suboptimal response to proteasome inhibition.

#### 442

#### 443 **Discussion**

444

Optimal management of HR-SMM continues to evolve with many novel approaches 445 446 currently under investigation to deliver highly effective therapy to prevent end-organ 447 damage while limiting toxicity. There have been phase III studies of lenalidomide and 448 dexamethasone demonstrating improvement in progression-free and overall survival and 449 there are ongoing studies utilizing triplets or quadruplets that include monoclonal 450 antibodies with proteasome inhibitors, lenalidomide, and dexamethasone. The ixazomib, 451 lenalidomide, and dexamethasone combination in this study demonstrated high response 452 rates with many patients experiencing deep responses, with VGPR or better in nearly half 453 of the patients treated as well as the benefit of an all-oral approach. No patients 454 progressed to overt MM during study therapy and the regimen was overall well-tolerated. 455 The response rates and safety were comparable to results seen in clinical trials of 456 ixazomib, lenalidomide, and dexamethasone of newly diagnosed and relapsed MM<sup>32,33</sup>. 457 The median PFS of 48.9 months also compares favorably to previously reported clinical 458 trials of triplet combination regimens in SMM<sup>19,20</sup>.

459

Because of the long follow-up of a median of 50 months and the depth of response
achieved in half of the patients, we have an opportunity to answer critical questions about
the management of early intervention in HR-SMM.

463

464 A controversial question in SMM trials is whether depth of response matters in trials of using lenalidomide alone or lenalidomide 465 HR-SMM. Previous studies and 466 dexamethasone demonstrated a long-term benefit and delay of end organ damage even if the best response was only PR. The argument was that immune equilibrium may be re-467 468 instated in those patients and deep remission is not required. However, other studies 469 using "curative intent" argued that achieving a depth of response similar to overt MM is 470 the most optimal way to achieve long-term remission. Here, we show for the first time that

471 a depth of response of VGPR or greater correlated with time to progression, suggesting
472 that deep response is impactful in SMM similar to overt MM. This was particularly
473 highlighted in patients with cytogenetically high-risk disease, where PFS was only 30.8
474 months in patients with less than VGPR.

475

The next question was whether MRD is associated with improved PFS. Although the numbers were small, we were still able to see near-significant differences in the PFS of MRD negative cases compared to those who did not achieve or sustain MRD negativity. Ongoing studies with deeper remissions with quadruplet therapy or immunotherapy will help further address this question more definitively.

481

482 We then examined the correlation of biochemical progression with the development of 483 SLIM-CRAB criteria. Thirty patients developed biochemical progression in all (27 after 484 completion of therapy), of which 8 patients also developed SLiM-CRAB with overt MM. 485 Eleven patients started new treatments on SMM-directed trials following the completion 486 of protocol therapy prior to developing SLiM-CRAB progression. Of these, ten 487 experienced biochemical progression while on follow-up and had an evolving pattern 488 leading to enrollment in a subsequent clinical trial. Four of these patients met high-risk 489 criteria per the 20/2/20 model. This is consistent with our clinical observation that patients 490 who opt to be treated initially for HR-SMM do not want to wait for the development of end-491 organ damage prior to re-initiating therapy, consistent with recent discussions to consider 492 biochemical progression as an end-point of therapy rather than SLiM-CRAB<sup>34</sup>. In addition, 493 it brings up a critical question of whether re-treatment on a trial of SMM should be in the 494 same cohort with other participants who were never exposed to therapy or in a separate 495 cohort. Additional guidance is necessary to determine which patients would be suitable 496 for further SMM-directed therapy vs MM induction therapy.

497

The strong correlation between biochemical progression and MDE also points out that biochemical progression can be used as a surrogate for MDE in high-risk SMM. However, the number of patients is small, and other studies need to further confirm this observation.

501

Interestingly, the use of 20/2/20 criteria in our study demonstrated that responses were similar across all risk criteria, but the progression-free survival was shortest for those who were high-risk per 20/2/20. This indicates that high-risk 20/2/20 patients may resemble MM and may require more aggressive therapy or maintenance therapy. We did not have an observation control arm in this study, so we cannot assess whether achieving response in these patients truly alters their long-term risk of progression to MM.

508

509 Moreover, the use of evolving subtype helped capture those with increasing biomarkers 510 regardless of their disease burden. The best response to treatment was not similar in those who showed increasing biomarkers prior to receiving therapy compared to those 511 512 who had fairly stable biomarkers. In patients who did not show an evolving disease pattern 513 as defined in our eligibility criteria, the best response to therapy achieved was better, 514 duration of response was longer, and their progression-free survival was superior 515 compared to those who demonstrated increasing biomarkers prior to therapy. Our study 516 highlights the benefit of including evolving disease as an indication of high-risk disease.

517 Future studies will help shed light on the importance of varying biomarkers in terms of risk 518 stratification and the severity of disease.

519

520 Genomic alterations are critical to better define patients who are truly at risk of progression and who may benefit from more aggressive therapy. In this study, the 521 522 addition of WGS and single-cell RNA sequencing helped identify participants with high-523 risk cytogenetics who otherwise would not have been identified by FISH alone. We opted 524 not to include MAPK and DNA repair pathway mutations in analyzing impact on outcomes 525 because we did not have data available on all patients. With additional data, we were able 526 to indeed define a population of high-risk cytogenetics and poor response to therapy who 527 showed the worst outcome.

528

529 Minimal residual disease was performed with two approaches in this protocol: standard 530 FDA-approved NGS on BM samples achieving at least VGPR and very sensitive MALDI-TOF mass spectrometry. MALDI-TOF was assessed on peripheral blood serum, avoiding 531 532 bone marrow biopsy, and is gaining more and more interest in the field. We showed that 533 MALDI-TOF is a sensitive and accurate assay for monitoring M protein isotype and 534 quantification, with a concordance with SPEP at baseline and a strong prognostic effect after EOT. We showed that MALDI-TOF is superior to IFX with 100% NPV and 83% PPV, 535 536 similar to previous studies<sup>35</sup>.

537

538 We performed an integrative study combining WGS and single-cell RNA-sequencing of 539 tumor and immune cells with the IRD study. To identify tumor-specific gene expression 540 differences that associated with IRD treatment response, we compared gene expression 541 tumor cells at baseline from progressor and non-progressor patients in who 542 received IRD. We observed significantly higher levels of MHC class I genes in tumor cells 543 from non-progressor patients compared to progressors. We further validated this finding 544 using data from an external study on MM patients treated with a different proteasome 545 inhibitor (Bortezomib), suggesting a broader link between MHC-I levels and response to 546 proteasome inhibition. To further explore the immune system's involvement, we 547 analyzed cytotoxic CD8+ T cells, which recognize and eliminate cells presenting specific 548 antigens on their surface via MHC-I molecule. We compared the clonal expansion of two 549 T cell subsets, granzyme K (GZMK)+ and granzyme B (GZMB)+, and found that 550 progressors exhibited greater clonal expansion in the GZMK+ compartment compared to 551 non-progressors, suggesting a potentially ineffective immune response. We have previously shown that the GZMK+ compartment is the major source of expression of PD-552 1, a key T cell exhaustion marker <sup>20</sup>. Additionally, progressors showed a reduced 553 554 proportion of the GZMB+ phenotype within their clonally expanded T cells, 555 suggesting their clonally expanded T cells have a less mature cytotoxic profile compared 556 to those of non-progressors. We next analyzed functional differences in T cells between progressors and non-progressors. Gene expression patterns revealed higher expression 557 558 of genes related to cytotoxicity and activation in the non-progressors' clonally expanded 559 GZMB+ T cells compared to those of the progressors. Clonally expanded GZMB+ T 560 cells from progressors showed increased expression of genes associated with apoptosis 561 and suppression of cytotoxic responses, alongside markers of maturation. This suggests 562 a more complex picture of functionality in these T cells from progressors. Our findings

563 suggest that immune dysfunction related to changes in tumor intrinsic antigen 564 presentation at baseline may contribute to suboptimal responses in proteasome inhibitor 565 therapy.

566

Our study has several limitations including the non-randomized nature of the trial without 567 a control arm and the potential selection bias in any single-center experience. Several 568 569 questions remain, including optimal timing of therapy in HR-SMM, duration of therapy, 570 treatment modality (combinations, immunotherapy), and response adaptive approaches. 571 The limited size of the scRNAseg sub-cohort and lack of functional validation limit the 572 conclusiveness of the findings and require further validation in larger, independent 573 cohorts.

574

575 In conclusion, this is the first trial studying an all-oral triplet combination of ixazomib, 576 lenalidomide, and dexamethasone in HR-SMM, demonstrating substantial efficacy and 577 identifying several factors critical in the outcome of patients: depth of response, evolving 578 pattern, MRD negativity and high risk 20/2/20. Future studies using guadruplet therapy or 579 immunotherapy may alter these conclusions. 580

#### 581 Methods

582

583 The research study was approved by the Dana-Farber/Harvard Cancer Center 584 institutional review board (protocol number DFCI 16-313) and complied with all relevant 585 ethical and legal regulations. All participants gave written informed consent. The clinicaltrials.gov registration number is NCT02916771. Individual deidentified participant 586 587 sequencing and FISH data will be shared.

588

#### 589 Eligibility Criteria

590

591 Patients enrolled on the study met eligibility for high-risk SMM based on criteria by 592 Rajkumar<sup>24</sup> as follows: bone marrow plasmacytosis  $\geq$  10% and  $\leq$ 60% and any one or 593 more of the following: serum M protein  $\geq 3$  g/dL, IgA isotype, immune paresis with 594 reduction of 2 uninvolved immunoglobulins, serum involved/uninvolved ratio of ≥8 but 595  $\leq$ 100, bone marrow plasmacytosis 50-60%, abnormal plasma cell immunophenotype, 596 high-risk FISH defined as t(4;14), del 17p or 1q gain, increased circulating plasma cells, 597 MRI with diffuse abnormalities or 1 focal lesion, PET/CT with one focal lesion with 598 increased uptake without underlying osteolytic bone destruction and urine monoclonal 599 light chain excretion ≥500mg/24 hours. Patients with evidence of SLiM-CRAB criteria 600 were excluded (bone marrow plasmacytosis > 60%, light chain ratio >100)<sup>36</sup>. Patients 601 were required to have an ECOG performance status of  $\leq 2$  and adequate hematologic and 602 organ function prior to enrollment. A creatinine clearance of  $\geq$ 30 mL/min was required.

603

#### 604 Treatment Regimen

605

Patients were treated on an outpatient basis with 9 cycles of induction therapy consisting 606 607 of ixazomib 4mg given orally on days 1, 8, and 15, in combination with lenalidomide 25mg 608

administered orally on days 1 through 21 and dexamethasone 40mg administered orally

609 on days 1, 8, 15, and 22 of a 28-day cycle. The induction phase was followed by maintenance therapy, consisting of ixazomib 4mg on days 1, 8, and 15 and lenalidomide 610 15mg on days 1-21 without dexamethasone for another 15 cycles. Treatment duration 611 612 was a total of 24 cycles (2 years).

613

#### 614 **Objectives and End Points**

615

616 The primary objective was to determine the proportion of patients with HR-SMM who are 617 progression-free 2 years after receiving trial therapy. Progression for the primary endpoint 618 was defined as the development of end organ damage per SLiM-CRAB criteria. 619 Secondary objectives included response rates, duration of response, progression-free 620 survival, safety of the combination therapy, and minimal residual disease (MRD) 621 negativity. Mass spectrometry analysis was also performed to correlate with IMWG 622 response and MRD status.

- 623
- 624

#### Minimal Residual Disease Assessment and Mass Spectrometry

625

626 MRD was assessed by the next-generation sequencing (NGS) ClonoSEQ® assay 627 (Adaptive Biotechnologies, Seattle, WA, USA) on bone marrow samples from patients 628 who achieved at least a very good partial response (VGPR) at cycle 9 (C9) or later. When 629 BM was available, a second MRD assessment was performed to confirm the MRD result. 630 Quality control (QC) of NGS results was performed as previously described<sup>37</sup>.

631

632 Minimal residual disease by next-generation sequencing was evaluable in 25 patients 633 who achieved at least a VGPR. Baseline pre-treatment bone marrow samples were 634 available for 22/25 patients and were analyzed for the identification of the VDJ molecular 635 marker by the Adaptive MRD assay. Twenty out of 22 (91%) baseline samples passed the QC analysis, and the molecular marker was identified in 18/22 patients (82%). For 636 637 MRD analysis of these 18 patients, bone marrow samples that were available from end 638 of induction (C9) and from the end of treatment (EOT) were used for sequencing. Three 639 of the 18 patients did not have any sample available for MRD analysis and one sample 640 had indeterminate results at limits of detection, 13 patients had MRD testing at the end of 641 induction (C9), 10 at EOT, and 8 individuals had an assessment at both timepoints for an 642 overall total of 23 samples tested for MRD.

643

644 Residual disease after therapy was also assessed by matrix-assisted laser desorption ionization-time of flight (MALDI-TOF) mass spectrometry to quantify M proteins (Binding 645 646 Site Group, Birmingham, UK), and Optilite free light-chain assay to quantify IgG, IgA, IgM, 647 and serum free light chains. EXENT-iQ software (Binding Site Group, Birmingham, UK) was used for quantitative analysis of detected M proteins. The lower limit of accurate M 648 649 protein quantification by MALDI-TOF mass spectrometry was 0.015 g/L. Serum (500 µL) was tested using the EXENT system and immunoglobulin (Ig) isotype assay<sup>38</sup>. The unique 650 mass/charge (m/z) (+/- 5) of a monoclonal light chain and the isotype were defined at 651 baseline and tracked in each patient's samples after therapy at the end of induction (C9) 652 653 and when available during maintenance (2-3 months after C9) and at end of treatment 654 (EOT). MALDI-TOF was performed at baseline before treatment in 48 patients out of 55.

655 Seven out of 55 patients were excluded due to sample unavailability (n = 5/7) and light 656 chain-only disease at baseline (n = 2 out of 55), defined as having a negative SPEP and serum immunofixation (IFX) result in the setting of SMM (Suppl Figure S2). We assessed 657 658 the concordance between Isotype by MALDI-TOF and SPEP-IFX and the correlation 659 between quantified M protein at baseline with the two methods using Pearson correlation. 660 The concordance between NGS MRD results and residual disease by MALDI-TOF was 661 also assessed by comparing the presence of residual M protein >0.015 g/L (limit of 662 detection)<sup>39</sup> and positivity at 10<sup>-5</sup> by NGS. Concordance between MS by MALDI-TOF, IFX, and NGS in BM was assessed using Cohen's kappa ( $\kappa$ ) statistic, with  $\kappa$  value 663 664 interpretation per Landis and Koch<sup>40</sup>.

665

#### 666 DNA isolation and library construction

Genomic DNA isolation was carried out using the Monarch Genomic DNA Purification Kit 667 (New England Biolabs), with tumor (PCs) and normal (PBMCs) yields quantified by Qubit 668 3.0 fluorometer (Thermo Fisher Scientific). 50-100ng was taken forward for DNA 669 670 sequencing library preparation using the NEBNext Ultra II FS DNA Library Prep kit (New England Biolabs) with unique dual index adapters (NEBNext Multiplex Oligos) according 671 to manufacturers' instructions. Final library fragment sizes were assessed using the 672 BioAnalyzer 2100 (Agilent Technologies), and yields were quantified by Qubit 3.0 673 674 fluorometer (Thermo Fisher Scientific) and qPCR (KAPA Library Quantification Kit).

675

#### 676 Whole genome sequencing (WGS) and genomic data analysis

WGS was available for 17 patients. Final sample libraries were normalized and pooled 677 before WGS was performed on Illumina NovaSeq 6000 S4 flow cells, 300 cycles 2x150bp 678 679 paired-end reads, at the Genomics Platform of the Broad Institute of MIT and Harvard. 680 WGS analysis was performed on an in-house cloud-based HPC system for copy-number and structural variant analyses, as previously described<sup>41</sup>. Sequencing reads were 681 aligned to the GRCh38 reference genome with the bwa mem v0.7.7 algorithm<sup>42</sup>, duplicate 682 683 reads were marked with MarkDuplicates from picard v1.457, indels were realigned with 684 GATK 3.4 IndelRealigner, and base gualities were recalibrated with GATKBQSR. WGS analysis was performed with the Cancer Genome Analysis workflow from the Cancer 685 686 Program at Broad Institute of MIT and Harvard on an in-house cloud-based HPC system. Small indels were called with Strelka2 and were filtered (i) against a panel of normals 687 (PoN), (ii) for potential technical artifacts (oxoG), and (iii) for multiple alignment with 688 689 BLAT<sup>43</sup>. After copy-number normalization with AllelicCapSeq, ABSOLUTE solutions were 690 manually reviewed to estimate mutation CCF, purity, and ploidy of tumor samples<sup>44</sup>. 691 Structural variants were detected and filtered as previously described<sup>45</sup>.

692

#### 693 Patient sample processing for scRNA-seq

Whole bone marrow aspirates (5-20mLs) were drawn into EDTA preservative tubes and kept at 4°C before being processed within a 6 hours from collection. Bone marrow mononuclear cells were isolated from aspirates using density gradient centrifugation. Briefly, the bone marrow was filtered to remove any clots or bone debris, diluted 1:3 with 1X Phosphate-Buffered Saline (PBS), and gently poured above 15mLs of Ficoll-Paque density gradient medium within a SepMate<sup>™</sup> PBMC isolation tube (StemCell Technologies, Cat # 85450). After centrifugation at 1200 rcf/g for 15 minutes, PBMCs

701 were poured away from unwanted cells and washed twice with ice-cold 1xPBS prior to plasma cell enrichment. Plasma cells were enriched from the bone marrow samples using 702 703 CD138 magnetic bead separation using single-column positive selection (Miltenyi Biotec, Cat #130-097-614).

704

705

706

Single-cell RNA/V(D)J library construction and sequencing 707

708 Sequencing libraries were prepared from BM samples, including 5' scRNA-seq libraries 709 and scBCR-seq and scTCR-seq libraries. After MACS enrichment, all CD138+ and 710 CD138- cells were centrifuged at 300 rcf/g for 5 mins and washed twice with an ice-cold 0.1% Ultrapure Bovine Serum Albumin (BSA)/PBS wash buffer. Subsequently, cells were 711 712 either subjected to volume reduction or diluted based on cell counts obtained using both 713 a hemocytometer and a Countess automated cell counter (ThermoFisher) and cell 714 mixtures were adjusted to obtain optimal cell densities for achieving maximal cell 715 recovery. Samples, Gel bead-in-EMulsion (GEMs), and partitioning oil were loaded into 716 a Next GEM Chip K microfluidic device and placed in a Chromium Controller instrument 717 for downstream single-cell encapsulation and recovery. All GEM generation/barcoding, post GEM RT clean-up/cDNA amplification and 5' gene expression (GEX) library 718 719 construction steps were completed using the Chromium Next GEM Single Cell 5' Reagent 720 Kit v2 (Dual Index) and Library Construction Kit, according to the manufacturer's instructions. cDNA generated was also subsequently subjected to V(D)J amplification 721 722 using Chromium Single Cell Human BCR Amplification Kit and Library Construction Kit for scBCR-seq and Chromium Single Cell Human TCR Amplification Kit and Library 723 724 Construction Kit for scTCR-seq, according to the manufacturer's instructions. The quality 725 of sample libraries was assessed based on library trace fragment sizes and patterns at 726 numerous points throughout the protocol including cDNA generation, BCR V(D)J preamplified cDNA generation, TCR V(D)J pre-amplified cDNA generation, final GEX, final 727 728 BCR and final TCR construction steps using a High-Sensitivity DNA Analysis Kit and the 729 Bioanalyzer 2100 instrument (Agilent Technologies). Final GEX, BCR and TCR library 730 quantification was performed using Quant-iT Picogreen dsDNA Assay Kit (Invitrogen) before preparing single pools for sequencing. Pooled libraries were sequenced on 731 732 NovaSeg S4 flow cells at the Genomics Platform of the Broad Institute of MIT and Harvard (Cambridge, MA).

733

734 735

Single-cell RNA/V(D)J data processing 736

CD138+ scRNA-seq was available for 13 patients, CD138- scRNA-seq was available for 737 738 20 patients and 12 patients had paired CD138+ and CD138- scRNA-seq. Paired WGS 739 and CD138+ RNA sequencing was available for 10 patients. 20 patients had either 740 scRNA-seg or WGS performed on their tumor samples.

CellRanger mkfastg (v5.0.1) was used to generate FASTQ files<sup>46</sup>. Gene expression 741 742 matrices were generated by CellRanger count (v6.0.1) with the genome reference 743 (refdata-gex-GRCh38-2020-A) provided by 10X Genomics<sup>46</sup>. To remove ambient RNA, 744 CellBender (v0.2.0) was run on the gene expression matrices with the target false positive 745 rate cutoff of 0.01. Poor quality cells with >15% mitochondrial gene expression, either

<200 detected genes, >5,000 detected genes, <400 UMIs, or >50,000 UMIs were filtered 746

out. Three doublet tools, Scrublet (v0.2.3), scDblFinder (v1.8.0), and scds (1.10.0) were used to calculate multiplet scores<sup>47-49</sup>. CellRanger vdj (v6.0.1) was used on FASTQ files

- 749 with the VDJ reference file (refdata-cellranger-vdj-GRCh38-alts-ensembl-5.0.0)<sup>46</sup>.
- 750
- 751 Malignant plasma cell identification

Plasma cells were first identified based on expressing key lineage markers, such as 752 753 SDC1 (encoding CD138), CD38, XBP1, PRDM1, IRF4, and TNFRSF17 (encoding 754 BCMA). Cell barcodes that were determined to correspond to plasma cells were 755 considered for downstream analysis. Tumor cells were identified on the basis of belonging 756 to the largest expanded BCR clone and clustering separately from normal plasma cells. 757 For all clones, the isotype of the malignant clone matched that detected clinically via IFX. 758 We annotated 50,591 of patient cells as tumor, and the rest (n=1876) as healthy plasma 759 cells based on our tumor cell annotation protocol. The median number of tumor cells per 760 patient was 2,148.

- 761
- 762 Single-cell TCR sequencing data processing and analysis
- We performed single-cell TCR sequencing on CD138- samples with available single-cell RNA sequencing data (n=9). Complementary DNA generated from barcoded CD138immune cells using Chromium Single Cell 5' Gene Expression and V(D)J enrichment kits by 10X Genomics was subjected to V(D)J enrichment and library preparation and sequenced on a NovaSeq 6000 instrument at the Genomics Platform of the Broad Institute of MIT & Harvard.
- 769 CellRanger v5.0.1 was used to extract FASTQ files and produce clonotype matrices<sup>50</sup>.
- 770 When multiple alignments were called for a single chain, the alignment with the most
- UMIs was selected, and when multiple chains were called for a single cell barcode, the
- top two chains in terms of UMI counts were selected.
- 773 Clone size assignment:
- To categorize TCR clones based on its size or its abundance within a sample, we employed a downsampling approach to account for potential sampling bias. We randomly sampled 100 T cells from each patient sample 100 times. Within each iteration, we calculated the proportion of each unique TCR clone compared to the total T cells sampled. Finally, for each clone, we averaged its proportional abundance across all iterations to obtain a more stable estimate of its size category. Categories were defined as: Rare:  $\leq 1\%$ , Small: > 1% and < 5%, Medium:  $\geq 5\%$  and < 10%, Large:  $\geq 10\%$ .
- 781 Clone-size-category proportion estimation within cell subtypes per patient sample:
- To estimate the overall proportion of clones belonging to each size category within a cell subtype per patient sample, we again used downsampling. We randomly sampled 100 T cells from each patient cell subtype sample 100 times. In each iteration, we counted the frequency of each clone size category within the downsampled set. Finally, we averaged the frequency of each category across all iterations and these averaged frequencies were
- then renormalized before plotting. Two-sided p-values were computed by bootstrapping
- with 1000 iterations.
- 789
- 790 Copy number analysis from scRNA sequencing

791 Copy number abnormalities on tumor cells were inferred using Numbat with default 792 parameters  $(v1.1.0)^{22}$ . Allelic data was collected from plasma cells and B cells and a panel 793 of 1,200 plasma cells from 11 healthy donors was used as expression reference.

794

#### 795 Differential Expression Analysis

796 Droplets with < 20,000 reads per cell were discarded, and 20,000 reads per cell were 797 downsampled across the entire CD138pos scRNA-seq cohort. To control the influence of 798 individual tumors on the analysis, as well as control for the lower number of non-799 progressors in this sub-cohort (n=3, compared to 10 progressors), we randomly sampled 800 the same number of tumor cells from progressors and non-progressors (~2100 per group) 801 and balanced the contribution of each individual towards the group (progressors: 210 cells 802 per patient as one progressor patient had fewer than 210 cells (n=72) after downsampling; 803 non-progressors: 700 cells per patient). We repeated this process leaving out the one 804 progressor patient with low number of cells this time considering only 9 progressor 805 patients and 3 non-progressors and once again balancing the contribution of each 806 individual towards the group (progressors n=225, non-progressors n=675 per patient). No 807 difference in results was observed.

808

#### 809 Statistical Analysis

810 The primary outcome was progression-free survival after two years of study treatment.

811 Progression-free was defined as being followed for at least two years from the start of

812 protocol therapy and no confirmed disease progression. The primary endpoint was

calculated for both progression to SLIM-CRB criteria as well as biochemical progression.

For this manuscript, progressive disease was defined as per the IMWG uniform response criteria for MM with either SLIM-CRAB progression or a rise of 25% in serum

817 or urine M protein or difference between involved and uninvolved FLC levels<sup>51</sup>.

818

Patients who did not have at least 2 years of follow-up or progressed between the start of treatment and two years after EOT were counted as failed progression-free at 2 years. The study was designed for a 50 vs 70% progression-free rate with 5% and 10% type I and type II errors, respectively. The critical value to reject the null hypothesis of 50% was

- 823 33 or more of 53 patients and was evaluated using a one-sided exact binomial test.
- 824

We report the primary outcome and responses to study treatment as proportions with 90% exact binomial confidence intervals. Continuous measures are summarized by median and range, and categorical variables are summarized as proportions.

Categorical variables were tested for association with continuous and other categorical variables using Wilcoxon rank-sum (or Kruskal-Wallis for three or more groups) or Fisher's exact tests, respectively. Time-to-event endpoints are estimated using the method of Kaplan and Meier with 95% confidence intervals calculated using Greenwood's method to estimate variance. Median follow-up is calculated using the reverse Kaplan-Meier method. Statistical analyses were performed using R version 4.1.2 (2021-11-01).

835

#### 836

#### 837 Acknowledgments

838

839 The authors would like to thank the patients and their families for participating in this 840 study.

- Anna V. Justis, PhD, a medical writer employed by Dana-Farber Cancer Institute, edited
- this manuscript under the direction of the authors.
- 843

### 844 Authorship Contributions

- 845
- 846 O.N.: Writing-Original Draft, Writing-Review & Editing
- 847 M.P.A.: Writing-Original Draft, Investigation, Formal analysis, Visualization, Writing-
- 848 Review & Editing
- 849 R.A.R.: Formal analysis, Visualization, Writing-Review & Editing
- 850 M.T: Formal analysis, Visualization, Writing-Review & Editing
- 851 S.M.: Writing-Review & Editing
- 852 J.A. Writing-Review & Editing, Supervision
- 853 L.B.: Investigation, Writing-Review & Editing
- 854 A.D. Writing-Review & Editing, Supervision
- 855 H.E.: Investigation, Writing-Review & Editing
- 856 M.B.: Investigation, Writing-Review & Editing
- 857 E.D.L.: Investigation, Writing-Review & Editing
- 858 J.P.L.: Writing-Review & Editing
- 859 G.B.: Writing-Review & Editing
- 860 E.O.: Writing-Review & Editing
- 861 T.W.: Writing-Review & Editing
- 862 J.T.: Writing-Review & Editing
- 863 K.A.: Writing-Review & Editing
- 864 P.G.R.: Writing-Review & Editing
- 865 G.G.: Writing-Review & Editing
- 866 L.T.: Writing-Review & Editing, Supervision
- 867 R.S.P.: Writing-Review & Editing, Supervision
- 868 I.M.G.: Conceptualization, Resources, Writing-Review & Editing, Supervision, Funding
- 869 Acquisition
- 870
- 871

#### 872 **Declaration of Interests**

- 873
- 874 ON: Research support from Takeda and Janssen; Advisory board participation: Bristol
- 875 Myers Squibb, Janssen, Sanofi, Takeda, GPCR therapeutics. Honorarium:Pfizer
- 876 M.P.A: No conflicts of interest exist.
- 877 R.A.R.: No conflicts of interest exist.
- 878 M.T: No conflicts of interest exist.
- 879 S.M.: No conflicts of interest exist.
- 880 J.B.A. No conflicts of interest exist.

- 881 L.B.: No conflicts of interest exist.
- 882 A.K.D. No conflicts of interest exist.
- 883 H.E.: No conflicts of interest exist.
- 884 M.B.: Consultancy with Janssen, BMS, Takeda, Epizyme, Karyopharm, Menarini
- 885 Biosystems, and Adaptive.
- 886 E.D.L.: No conflicts of interest exist.
- 387 J.P.L.: No conflicts of interest exist.
- 888 G.B.: Consultancy: Prothena
- 889 E.O.: Advisory Board/Honoraria: Janssen, BMS, Sanofi, Pfizer, Exact Consulting-
- 890 Takeda Steering Committee: Natera
- 891 T.W.: No conflicts of interest exist.
- 892 J.T.: No conflicts of interest exist.
- 893 K.A.: Consultant: AstraZeneca, Janssen, Pfizer, Board/ Stock Options: Dynamic Cell
- 894 Therapies, C4 Therapeutics, Next RNA, Oncopep, Starton, Window
- 895 G.G.: No conflicts of interest exist.
- 896 L.T.: No conflicts of interest exist.
- 897 P.G.R.: Advisory Boards/Consulting: Celgene/BMS, GSK, Karyopharm, Oncopeptides,
- 898 Regeneron, Sanofi, Takeda. Research Grants: Oncopeptides, Karyopharm
- 899 R.S.P.: Co-founder, equity holder, and consultant on pre-seed stage startup.
- 900 I.M.G.: Consulting/Advisory role: AbbVie, Adaptive, Amgen, Aptitude Health, Bristol
- 901 Myers Squibb, GlaxoSmithKline, Huron Consulting, Janssen, Menarini Silicon
- Biosystems, Oncopeptides, Pfizer, Sanofi, Sognef, Takeda, The Binding Site, and
- 903 Window Therapeutics; Speaker fees: Vor Biopharma, Veeva Systems, Inc.; I.M.G.'s
- 904 spouse is CMO and an equity holder of Disc Medicine.
- 905

#### 906 Inclusion and Ethics

- 907 One or more of the authors of this paper self-identifies as an underrepresented ethnic 908 and/or gender minority in science. One or more of the authors of this paper self-identifies 909 as a member of the LGBTQIA+ community. We support inclusive, diverse and equitable 910 conduct of research.
- 910 conduct of research 911

#### 912 **Data availability**

- 913 Single-cell RNA and TCR-sequencing raw data generated for this study will be deposited
- 914 in dbGaP (study site pending). Gene expression matrices can be accessed on Mendeley:
- 915 https://data.mendeley.com/preview/z56k3y8cdg?a=6945f72a-b190-4fb1-b0fe-
- 916 31c12a70a0d4 (reserved DOI:10.17632/z56k3y8cdg.1)
- 917
- 918

#### 919 Code Availability

- 920 This paper does not report original code.
- 921

#### 922 Figure Legends

923

924 Figure 1. A) Consort Diagram B) Primary events such as translocations and 925 hyperdiploidy and secondary events such as copy number alterations identified by 926 FISH, WGS, and scRNA-seg along with response to therapy. WGS = Whole genome 927 sequencing, scRNA = Single-cell RNA sequencing. scRNA-seq revealed a more complex 928 aberration in one case (HRD with trisomies of chromosomes 5, 9, 11, 15, 19, and 21) compared 929 to whole-genome sequencing (WGS) which only detected trisomies on chromosomes 9 and 15. 930 This explains the apparent discrepancy between WGS finding "no primary event" and scRNA-931 seq identifying HRD (homologous recombination deficiency) in that case. ND=Not determined, 932 CR=Complete response, VGPR=Very good partial response, PR=Partial response, MR=Minimal 933 response, SD=Stable disease. 934 935 Figure 2. Swimmer's plot of responses deepening over time. Each lane represents 936 one participant. 937 938 Figure 3. Progression-free and overall survival. Progression defined by A) 939 Biochemical progression or **B**) SLiM CRAB criteria **C**) Overall survival. NR = not 940 reached **D**) Kaplan-Meier curve of response duration stratified by 20/2/20 risk groups. 941 E) Kaplan-Meier curve of progression stratified by 20/2/20 risk groups. Survival 942 distributions were compared using one-sided log-rank tests. 943 944 Figure 4. Outcomes stratified by the presence of evolving subtype prior to 945 treatment. A) Overall survival B) progression-free survival C) time-to-progression and 946 **D)** duration of response. NR = not reached. Survival distributions were compared using 947 one-sided log-rank tests. 948 949 Figure 5. Kaplan Meier Curve of Progression-Free Survival based on A) Depth of 950 Response of VGPR of greater. VGPR = Very good partial response B) depth of 951 response amongst cytogenetically high-risk patients by High-risk patients identified by 952 FISH alone. C) by High-risk patients identified by FISH, WGS, or single-cell RNA 953 sequencing. D) Kaplan-Meier curve of duration of response stratified by patients who 954 achieved sustained CR. E) Kaplan-Meier curve of progression-free-survival stratified by 955 patients who achieved sustained CR. CR = Complete response. Survival distributions 956 were compared using one-sided log-rank tests. 957 958 Figure 6. Kaplan Meier Curve of Outcomes Based on MRD Status: A). Overall 959 Survival, B) Progression-free survival. Survival distributions were compared using one-960 sided log-rank tests. 961 962 Figure 7. Single-cell RNA sequencing of bone marrow CD138+ cells. A) Time to 963 progression or last follow-up for the subcohort of patients with sequencing data (one

964 patient per row). The type of sequencing data available for individual patients is

indicated by green boxes. Patients are grouped by progression status. **B)** Uniform

manifold approximation and projection (UMAP) embeddings of patients' and HD's
 plasma cells that passed quality filtering Cells are colored by the patient from which

968 they originate or patients or HD as a group C) UMAP colored by malignancy status 969 (tumor vs normal cells). D) UMAP colored by biochemical progression status. E) Volcano plot of differential gene expression in progressors and non-progressors. Two-970 971 sided p values were computed with Wilcoxon's rank-sum test and corrected using the 972 Benjamini-Hochberg approach. The top 30 genes on either side of the volcano with q < 973 0.05 are indicated by stars. F) HLA class lexpression in patients from the PADIMAC 974 cohort who responded (bortezomib good) or did not respond (Bortezomib standard) to 975 bortezomib treatment. Single-cell RNA sequencing of T cells from CD138- samples. G) 976 UMAP of Tcells H) Bar plot visualizing the proportion of clonotypes belonging to each of 977 four clone size categories per patient in BM CD138- samples drawn at BL. For patient's 978 T cell subtype being analyzed, 100 cells were randomly sampled 100 times from non-979 progressor and progressor patients, and the proportion of expanded (1-rare) clonotypes 980 was compared between the two using bootstrapping with 1000 iterations. The average proportion per clone size category is visualized, and the SD across iterations is depicted 981 982 in solid-line error bars. I) Boxplots, violin plots, and scatterplots comparing the 983 abundance of GZMB+ CD8+ T effector memory (TEM) cells in expanded clones 984 between non-progressors and progressors. Two-sided p values were computed with 985 Wilcoxon's rank-sum test and corrected using the Benjamini-Hochberg approach. **J**) 986 UMAP embedding of progressor and non-progressor patients' BM T cells at BL with 987 matched TCR data. T cells with expanded clones (with a frequency > 1%) are colored 988 by cell type. Cells with rare clonotypes are shown in grey. K) Volcano plot of differential 989 gene expression of clonally expanded CD8 TEM in progressors and non-progressors. p 990 values were computed with Wilcoxon's rank-sum test and corrected using the 991 Benjamini-Hochberg approach. Top 30 genes on either side of the volcano with q < 0.05992 are indicated by stars. HD = healthy donors; P = patient; WGS = whole-genome 993 sequencing: HRD = hyperdiploidy994

995


#### 996 **References**


997	
998	1. Kyle RA, Remstein ED, Therneau TM, et al: Clinical course and prognosis of
999	smoldering (asymptomatic) multiple myeloma. N Engl J Med 356:2582-90, 2007
1000	2. Dispenzieri A, Kyle RA, Katzmann JA, et al: Immunoglobulin free light chain
1001	ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple
1002	myeloma. Blood 111:785-9, 2008
1003	3. Perez-Persona E, Vidriales MB, Mateo G, et al: New criteria to identify risk of
1004	progression in monoclonal gammopathy of uncertain significance and smoldering multiple
1005	myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells. Blood
1006	110:2586-92, 2007
1007	4. Rajkumar SV, Landgren O, Mateos MV: Smoldering multiple myeloma. Blood
1008	125:3069-75, 2015
1009	5. Lakshman A, Rajkumar SV, Buadi FK, et al: Risk stratification of smoldering
1010	multiple myeloma incorporating revised IMWG diagnostic criteria. Blood Cancer J 8:59, 2018
1011	6. Cowan A, Ferrari F, Freeman SS, et al: Personalised progression prediction in
1012	patients with monoclonal gammopathy of undetermined significance or smouldering multiple
1013	myeloma (PANGEA): a retrospective, multicohort study. The Lancet Haematology 10:e203-
1014	e212, 2023
1015	7. Hill E, Dew A, Morrison C, et al: Assessment of Discordance Among Smoldering
1016	Multiple Myeloma Risk Models. JAMA Oncology 7:132-134, 2021
1017	8. Bustoros M, Sklavenitis-Pistofidis R, Park J, et al: Genomic Profiling of
1018	Smoldering Multiple Myeloma Identifies Patients at a High Risk of Disease Progression. J Clin
1019	Oncol 38:2380-2389, 2020
1020	9. Bolli N, Maura F, Minvielle S, et al: Genomic patterns of progression in
1021 1022	<ul> <li>smoldering multiple myeloma. Nat Commun 9:3363, 2018</li> <li>10. Misund K, Keane N, Stein CK, et al: MYC dysregulation in the progression of</li> </ul>
1022	multiple myeloma. Leukemia 34:322-326, 2020
1023	11. Oben B, Froyen G, Maclachlan KH, et al: Whole-genome sequencing reveals
1024	progressive versus stable myeloma precursor conditions as two distinct entities. Nat Commun
1025	12:1861, 2021
1020	12. Boyle EM, Deshpande S, Tytarenko R, et al: The molecular make up of
1028	smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma. Nat
1029	Commun 12:293, 2021
1030	13. Mateos MV, Hernandez MT, Giraldo P, et al: Lenalidomide plus dexamethasone
1031	for high-risk smoldering multiple myeloma. N Engl J Med 369:438-47, 2013
1032	14. Lonial S, Jacobus S, Fonseca R, et al: Randomized Trial of Lenalidomide Versus
1033	Observation in Smoldering Multiple Myeloma. J Clin Oncol 38:1126-1137, 2020
1034	15. Goodman AM, Kim MS, Prasad V: Persistent challenges with treating multiple
1035	myeloma early. Blood 137:456-458, 2021
1036	16. Avet-Loiseau H, Bahlis NJ: Smoldering Multiple Myeloma : Taking the narrow
1037	over the wide path? Blood, 2024
1038	17. Ghobrial IM, Gormley N, Kumar SK, et al: Round Table Discussion on Optimal
1039	Clinical Trial Design in Precursor Multiple Myeloma. Blood Cancer Discovery:OF1-OF7, 2024
1040	18. Mateos MV LJ, Rodrigues-Otero P, et al. : Curative Strategy (GEM-CESAR) for
1041	High-Risk Smoldering Myeloma (SMM): Carfilzomib, Lenalidomide and Dexamethasone (KRd)

1042 As Induction Followed By HDT-ASCT, Consolidation with Krd and Maintenance with Rd. 1043 Blood 134:781, 2019 1044 19. Kazandjian D, Hill E, Dew A, et al: Carfilzomib, Lenalidomide, and 1045 Dexamethasone Followed by Lenalidomide Maintenance for Prevention of Symptomatic 1046 Multiple Myeloma in Patients With High-risk Smoldering Myeloma: A Phase 2 Nonrandomized 1047 Controlled Trial. JAMA Oncol 7:1678-1685, 2021 1048 Sklavenitis-Pistofidis R, Aranha MP, Redd RA, et al: Immune biomarkers of 20. 1049 response to immunotherapy in patients with high-risk smoldering myeloma. Cancer Cell 1050 40:1358-1373.e8, 2022 1051 Kumar SK, Alsina M, Laplant B, et al: Fixed Duration Therapy with 21. 1052 Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone for High Risk Smoldering 1053 Multiple Myeloma-Results of the Ascent Trial. Blood 140:1830-1832, 2022 1054 22. Gao T, Soldatov R, Sarkar H, et al: Haplotype-aware analysis of somatic copy 1055 number variations from single-cell transcriptomes. Nat Biotechnol 41:417-426, 2023 1056 Durie BG, Harousseau JL, Miguel JS, et al: International uniform response 23. 1057 criteria for multiple myeloma. Leukemia 20:1467-73, 2006 1058 24. Rajkumar SV, Dimopoulos MA, Palumbo A, et al: International Myeloma 1059 Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol 15:e538-1060 48, 2014 1061 25. Rajkumar SV: Updated Diagnostic Criteria and Staging System for Multiple 1062 Myeloma. Am Soc Clin Oncol Educ Book 35:e418-23, 2016 1063 Lonial S, Jacobus SJ, Weiss M, et al: E3A06: Randomized phase III trial of 26. 1064 lenalidomide versus observation alone in patients with asymptomatic high-risk smoldering 1065 multiple myeloma. Journal of Clinical Oncology 37:8001-8001, 2019 1066 Munshi NC, Avet-Loiseau H, Anderson KC, et al: A large meta-analysis 27. 1067 establishes the role of MRD negativity in long-term survival outcomes in patients with multiple 1068 myeloma. Blood Advances 4:5988-5999, 2020 1069 28. Daniele P, Mamolo C, Cappelleri JC, et al: Response rates and minimal residual 1070 disease outcomes as potential surrogates for progression-free survival in newly diagnosed 1071 multiple myeloma. PLoS One 17:e0267979, 2022 1072 Gulla A, Morelli E, Samur MK, et al: Bortezomib Induces Anti-Multiple 29. 1073 Myeloma Immune Response Mediated by cGAS/STING Pathway Activation. Blood Cancer 1074 Discovery 2:468-483, 2021 1075 30. Schnell S, Démollière C, van den Berk P, et al: Gimap4 accelerates T-cell death. 1076 Blood 108:591-599, 2006 1077 31. Tang J, Jia X, Li J, et al: Themis suppresses the effector function of CD8+ T cells 1078 in acute viral infection. Cellular & Molecular Immunology 20:512-524, 2023 1079 Facon T, Venner CP, Bahlis NJ, et al: Oral ixazomib, lenalidomide, and 32. 1080 dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma. Blood 1081 137:3616-3628, 2021 1082 Moreau P, Masszi T, Grzasko N, et al: Oral Ixazomib, Lenalidomide, and 33. 1083 Dexamethasone for Multiple Myeloma. New England Journal of Medicine 374:1621-1634, 2016 1084 34. Ghobrial IM, Gormley N, Kumar SK, et al: Round Table Discussion on Optimal 1085 Clinical Trial Design in Precursor Multiple Myeloma. Blood Cancer Discovery:OF1-OF7, 2024 1086 35. Puig N, Contreras MT, Agulló C, et al: Mass spectrometry vs immunofixation for 1087 treatment monitoring in multiple myeloma. Blood Adv 6:3234-3239, 2022


1088 36. Wu V, Moshier E, Leng S, et al: Risk stratification of smoldering multiple myeloma: predictive value of free light chains and group-based trajectory modeling. Blood Adv 1089 1090 2:1470-1479, 2018 1091 37. Perrot A, Lauwers-Cances V, Corre J, et al: Minimal residual disease negativity 1092 using deep sequencing is a major prognostic factor in multiple myeloma. Blood 132:2456-2464, 1093 2018 1094 38. El-Khoury H, Lee DJ, Alberge JB, et al: Prevalence of monoclonal gammopathies 1095 and clinical outcomes in a high-risk US population screened by mass spectrometry: a multicentre 1096 cohort study. Lancet Haematol, 2022 1097 Sakrikar D, Marrot N, North S, et al: Multi-Site Verification of the Automated 39. 1098 EXENT(R) MALDI-TOF-MS System and Immunoglobulin Isotypes Assay for the Identification 1099 and Quantification of Monoclonal Immunoglobulins, 2021 AACC Annual Scientific Meeting, 1100 2021 1101 40. Landis JR, Koch GG: The measurement of observer agreement for categorical 1102 data. Biometrics 33:159-74, 1977 1103 Dutta AK, Alberge JB, Lightbody ED, et al: MinimuMM-seq: Genome 41. 1104 Sequencing of Circulating Tumor Cells for Minimally Invasive Molecular Characterization of 1105 Multiple Myeloma Pathology. Cancer Discov 13:348-363, 2023 1106 Li H: Aligning sequence reads, clone sequences and assembly contigs with BWA-42. 1107 MEM. arXiv preprint arXiv:1303.3997, 2013 1108 Kim S, Scheffler K, Halpern AL, et al: Strelka2: fast and accurate calling of 43. 1109 germline and somatic variants. Nat Methods 15:591-594, 2018 1110 44. Carter SL, Cibulskis K, Helman E, et al: Absolute quantification of somatic DNA 1111 alterations in human cancer. Nat Biotechnol 30:413-21, 2012 1112 Morton LM, Karyadi DM, Stewart C, et al: Radiation-related genomic profile of 45. 1113 papillary thyroid carcinoma after the Chernobyl accident. Science 372, 2021 1114 Zheng GX, Terry JM, Belgrader P, et al: Massively parallel digital transcriptional 46. 1115 profiling of single cells. Nat Commun 8:14049, 2017 1116 Wolock SL, Lopez R, Klein AM: Scrublet: Computational Identification of Cell 47. 1117 Doublets in Single-Cell Transcriptomic Data. Cell Syst 8:281-291.e9, 2019 1118 48. Bais AS, Kostka D: scds: computational annotation of doublets in single-cell 1119 RNA sequencing data. Bioinformatics 36:1150-1158, 2020 Germain PL, Lun A, Garcia Meixide C, et al: Doublet identification in single-cell 1120 49. 1121 sequencing data using scDblFinder. F1000Res 10:979, 2021 1122 Zheng GXY, Terry JM, Belgrader P, et al: Massively parallel digital 50. 1123 transcriptional profiling of single cells. Nature Communications 8:14049, 2017 1124 Kumar S, Paiva B, Anderson KC, et al: International Myeloma Working Group 51. 1125 consensus criteria for response and minimal residual disease assessment in multiple myeloma. 1126 Lancet Oncol 17:e328-e346, 2016


1127






#### Figure 3








В. SLIM-CRAB PFS 100 Percent alive and progression-free 50 0 12 24 0 36 48 60 Months from treatment start Number at risk Median - 55 53 49 36 NR All -19


D































UMAP\_1

#### Table 1A. Baseline Characteristics

	(N = 55)
Median age – yr (range)	64 (40-84)
Male sex – no. (%)	30 (55%)
Race – no. / N (%)	
White/Caucasian	53 (96%)
Asian	1 (2%)
Other	1 (2%)
Ethnicity – no. / N (%)	
Hispanic	2 (4%)
Non-Hispanic	53 (96%)
ECOG performance status – no. / N (%)	
0	46 (84%)
1	9 (16%)
Smoldering myeloma disease type – no. / N%)	
lgG	37 (67%)
IgA	16 (29%)
Light chain only	2 (4%)
Evolving Disease– no. / N (%)	
Yes	29 (53%)
No	26 (47%)
Cytogenetic risk category – no. / N (%)	
High-risk [t(4;14), t(14;16), del(17p), 1q gain, del1p, del13q	35 (64%)
Standard-risk	14 (25%)
Not determined	6 (11%)
<sup>+</sup> Cytogenetic abnormalities - no. / N (%)	
t(4;14)	6 (11%)
t(14;16)	6 (11%)
del(17p)	3 (5%)
1q gain/amp	18 (33%)
t(11;14)	8 (15%)
Monosomy 13	26 (47%)
20/2/20 Risk	
High	25 (45%)
Intermediate	21 (38%)
Low	9 (16%)
Мауо 2008	
1 risk factor	13 (24%)
2 risk factors	40 (72%)
3 3isk factors	2 (4%)

<sup>†</sup> Cytogenetic abnormalities are compiled from FISH, scRNA-seq and WGS at screening or pre-screening timepoint. For one patient, a primary event translocation was taken from a post-screening timepoint. Cytogenetic data was unknown for 6 patients.

#### Table 1B. Baseline Risk Stratification

Iable		asem		onat	ification			High-						Total number
Patient ID	lgA Isotype ª	M- spike ≥ 3.0 <sup>b</sup>	lmmuno paresis <sup>c</sup>	FLC Ratio ≥ 8 <sup>d</sup>	Evolving Disease <sup>e</sup>	BMPC 50- 60% <sup>f</sup>	t(4;14) -17p +1q <sup>g</sup>	Risk cytogen etics FISH <sup>h</sup>	High-Risk cytogeneti cs FISH+Seq <sup>i</sup>	Mayo 2008	IMWG 20/2/20	IMWG High Precision	Number of High-Risk Criteria †	of eligibility criteria met (+BMPC ≥ 10%) ††
P1	1	0	0	1	1	0	0	0	0	Int	Int	Low-Int	1	3
P2	0	1	1	1	1	1	1	1	1	High	High	High	5	6
P3	1	0	1	0	0	0	0	0	0	Low	Int	Low	0	2
P4	0	0	1	1	1	0	N/A	N/A	0	Int	Low	Low	1	3
P5	0	0	0	1	1	0	0	1	1	Int	High	High	4	2
P6	1	0	0	0	0	0	1	1	1	Low	Low	Low	1	2
P7	1	0	1	0	0	0	0	1	1	Low	Int	Low-Int	1	2
P8	1	0	1	0	0	0	0	0	0	Low	Low	Low	0	2
P9	0	0	1	1	0	0	0	0	1	Int	High	Low-Int	2	2
P10	0	0	1	1	0	1	1	1	1	Int	Int	High	2	4
P11	0	0	1	1	1	0	1	1	1	Int	Int	Int	2	4
P12	1	0	0	0	1	0	1	1	1	Low	Low	Low	2	3
P13	0	0	1	1	0	0	1	1	1	Int	Low	Int	1	3
P14	0	0	1	0	0	0	N/A	N/A	N/A	Low	High	Low-Int	1	1
P15	0	1	0	0	1	1	0	0	0	Int	High	Int	2	3
P16	0	0	0	1	1	0	0	1	1	Int	High	Int	3	2
P17	0	1	0	1	0	1	1	1	1	High	High	High	4	4
P18	0	0	1	1	0	0	0	0	0	Int	High	High	2	2
P19	1	0	1	1	0	0	0	0	0	Int	Int	Int	0	3
P20	0	0	0	1	0	0	N/A	N/A	1	Int	Int	Low-Int	1	1
P21	1	0	0	0	1	0	N/A	N/A	N/A	Low	Low	Low	1	2
P22	0	0	0	1	0	0	1	1	1	Int	High	High	3	2
P23	0	0	0	1	1	0	N/A	N/A	N/A	Int	Low	Low	1	2
P24	0	0	1	1	1	1	1	1	1	Int	High	High	4	5
P25	1	0	1	1	0	1	1	1	1	Int	High	Int	2	5
P26	0	0	0	0	0	0	1	1	1	Low	Low	Low-Int	1	1
P27	0	0	0	1	0	0	0	1	1	Int	Int	Low-Int	1	1
P28	0	0	1	0	1	0	1	1	1	Low	High	Int	3	3
P29	0	0	0	1	1	0	0	0	0	Int	Int	Low-Int	1	2
P30	1	0	1	1	1	1	0	1	1	Int	High	Int	3	5
P31	0	0	1	1	1	0	0	0	0	Int	High	Low-Int	2	3
P32	0	0	1	1	1	1	0	0	1	Int	High	High	4	4
P33	0	0	1	1	1	1	1	1	1	Int	Int	Low-Int	2	5
P34	0	0	0	1	0	0	1	1	1	Int	High	Int	2	2
P35	0	0	0	1	1	0	N/A	N/A	N/A	Int	Int	Low-Int	1	2
P36	0	0	1	1	0	0	1	1	1	Int	Int	Int	1	3
P37	1	0	1	1	1	0	0	0	0	Int	Int	Int	1	4
P38	0	0	1 1	1	1	0	1	1	1	Int	High	High	4	4 1
P39 P40	0	0 0	1	0 1	0 1	0 0	0 0	0 1	0 1	Low	High	Low-Int	1	1 3
P40 P41	0	0	1 0	1	0	0	0 N/A		0	Int	Low	Low-Int Low-Int	2 0	3
			0	1	1			N/A		Int	Int			
P42 P43	1 0	0 0	1 0	1	1	0 0	0 N/A	1 N/A	1 N/A	Int	Int	Low-Int	2 1	4 2
P43 P44	0	0	0	1	1	0	N/A 0	N/A 1	N/A 1	Int	Int Int	Low-Int	2	2 3
P44 P45	1	0	1	1	1	0	1	1 1	1	Int Int	Int	Int Low-Int	2	3 5
P45 P46	1	0	1	1	1	0	1	1	1				•	-
P40 P47	1	0	0	0	0	0	1	1	1	Int Low	High Int	Int Low	3 1	5
P47 P48	0	0	1	0	0	0	0	1	1	Low	Int	Low-Int	1	2
P40 P49	0	0	1	1	1	0	N/A	N/A	N/A	Int	High	Low-Int	2	3
P50	0	0	0	1	1	0	0	1	1	Int	High	Int	3	2
P51	0	0	1	0	0	0	0	0	0	Low	High	Low-Int	1	1
P52	1	0	1	1	0	0	N/A	N/A	N/A	Int	High	Int	1	3
P53	1	0	0	1	0	0	1	1	1	Int	Int	Low-Int	1	3
P54	1	0	0	1	0	0	0	1	1	Int	High	Low-Int	2	2
P55	0	0	0	1	1	0	N/A	N/A	1	Int	High	High	4	2
	. ~	5	5		•	5	// .		•					-

Abbreviations: FLC, Free Light Chain; BMPC, Bone Marrow Plasma Cells; FISH, Fluorescent In-Situ Hybridization; Seq, Sequencing; Int, Intermediate. Columns <sup>a-g</sup> contain high-risk criteria as defined by Rajkumar et al<sup>4</sup>. High-Risk cytogenetics in columns <sup>h, I</sup> defined as t(4;14), t(14;16), 1q gain/amp, 13q deletion/monosomy 13, dedeletion 1p, and 17p deletion.

† Total Number of High-Risk Criteria by Mayo 2008, IMWG 20/2/20, IMWG High Precision, Evolving Disease, and High-Risk Cytogenetics by FISH+Seq

tt Total Eligibility criteria met for enrollment as described in Methods section.

All grades			
	Grade 2*	Grade 3*	Grade 4 <sup>a</sup>
55 (100)	20 (36)	34 (62)	5 (9)
43 (78)	18 (33)	14 (25)	2 (4)
33 (60)	4 (7)	4 (7)	1 (2)
44 (80)	21 (38)	10 (18)	
33 (60)	6 (11)	1 (2)	
15 (27)	4 (7)	6 (11)	2 (4)
27 (67)	5 (9)		
26 (47)	1 (2)		
33 (60)	3 (5)		
42 (76)	11 (20)	1 (2)	
31 (56)	3 (5)		
18 (33)	15 (27)	2 (4)	
14 (25)			
16 (29)	8 (15)	7 (13)	
13 (24)			
			1 (2)
10 (18)		3 (5)	1 (2)
32 (9.0)			
31 (56)	7 (13)		
38 (69)	11 (20)	5 (9)	
31 (56)	5 (9)		
	43 (78) 33 (60) 44 (80) 33 (60) 15 (27) 27 (67) 26 (47) 33 (60) 42 (76) 31 (56) 18 (33) 14 (25) 16 (29) 13 (24) 10 (18) 32 (9.0) 31 (56) 38 (69)	$\begin{array}{ccccccc} 43 & (78) & 18 & (33) \\ 33 & (60) & 4 & (7) \\ 44 & (80) & 21 & (38) \\ 33 & (60) & 6 & (11) \\ 15 & (27) & 4 & (7) \\ 27 & (67) & 5 & (9) \\ 26 & (47) & 1 & (2) \\ 33 & (60) & 3 & (5) \\ 42 & (76) & 11 & (20) \\ 31 & (56) & 3 & (5) \\ 18 & (33) & 15 & (27) \\ 14 & (25) \\ 16 & (29) & 8 & (15) \\ 13 & (24) \\ 10 & (18) \\ 32 & (9.0) \\ 31 & (56) & 7 & (13) \\ 38 & (69) & 11 & (20) \end{array}$	$\begin{array}{cccccccccccccccccccccccccccccccccccc$

#### Table 2. Summary of Adverse Reactions Reported During Treatment

	(N = 55)
Best response (IMWG) – no. (%)	
PR or better [95% CI]	51 (93) [84–97]
VGPR or better [95% CI]	25 (45) [32- 56]
CR*	17 (31)
VGPR	8 (15)
PR	26 (47)
*All patients with CR achieved stringent	CR

Table 3. Summary of Responses to Treatment